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Miracles do happen: meeting the challenges 




It begins with a phone call or an e-mail. “I have a patient 
with sickle cell disease with anti-X who will need chronic 
transfusions beginning…. We have a pregnant female sched-
uled to deliver in 3 months who has anti-X and a history of 
hemorrhaging during delivery…. There is a fetus who will need 
intrauterine transfusions because of maternal anti-X…. We 
will be managing a transplant patient with anti-X . . . can you 
help?”
Requests to the American Rare Donor Program (ARDP) 
are managed 24/7 by the American Red Cross (ARC) National 
Reference Laboratory for Blood Group Serology (NRLBGS) 
staff in Philadelphia, Pennsylvania. Staff members at the 89 
ARDP member Immunohematology Reference Laboratories 
(IRLs) across the United States and abroad submit requests to 
the Philadelphia staff who relay the request to the other ARDP 
members who then search their inventories for available units 
or eligible donors.1,2 This process works well; the ARDP has a 
93.8 percent fill rate (average of years 2004–2014), which is 
defined as providing at least 1 unit of rare blood for each request. 
While units of rare blood can be frozen to meet a future need, 
frozen units have a propensity to break in transit. Therefore, 
it is preferable, if time allows, that requests for exceptionally 
rare blood of which there are less than a handful of donors, 
requests for blood for a patient requiring chronic transfusions 
whose serum contains multiple antibodies necessitating rare 
blood and requiring a more extensive search, and international 
requests for which shipping may involve multiple flights and 
customs clearance be handled by the recruitment, collection, 
and shipping of liquid red blood cell (RBC) units. It is these 
requests that require an intense search to find the one donor 
who matches a patient and then to ship that precious unit 
across state and sometimes international borders. These are 
the requests for which a phone call or an e-mail to the ARDP 
manager starts a different process: one that requires a high 
degree of collaboration between shipping and receiving 
facilities. 
The ARDP serves its member facilities, non-member 
facilities that use a member as a portal to access the program, 
as well as its international colleagues when they are unable 
to provide units for a patient. From 2005 to 2015, the ARDP 
provided 19,528 rare RBC units for 9683 patient requests 
within the U.S. and 172 units for 77 requests internationally. 
However, at times, providing rare blood requires a miracle to 
overcome the many challenges, some of which are highlighted 
in this article.
One obvious challenge is finding the especially rare units 
or eligible donors when a request is made. Communication 
with the ARDP members provided knowledge as to which 
members had coveted K0 donors, which members had En(a–) 
units in their freezer, or how to obtain the most rare Rhnull units 
through a personal conversation with our only known Rhnull 
donor, who was very knowledgeable about her phenotype and 
its impact on her life as well as its rarity and need. She donated 
numerous autologous as well as allogeneic units that she 
gladly released for other patients with the stipulation that she 
be notified of the request and that the patient truly “needed” 
Rhnull blood (i.e., had the respective antibodies). She would 
then donate to ensure an adequate supply of units for herself as 
well as for others: a truly altruistic, informed rare donor! 
An associated challenge is providing especially rare blood 
in a time-sensitive situation. One of the most miraculous of 
the international experiences involved the turnaround time 
to fill a request from New Zealand for a pregnant female who 
was group A, D+ with anti-Rh17, for whom they requested 2 
units of “fresh” (less than 5 days old), group O, D–– RBCs 
for the baby. The ARDP received the request on a Tuesday. At 
that time, there were eight registered group O, D–– donors 
in the ARDP database; however, only three donors could be 
contacted immediately on that Wednesday. All three donors 
attempted to donate; one was deferred. The 2 liquid units 
were shipped to Philadelphia on Friday and shipped to New 
Zealand, arriving 7 days from the initial request—not quite 5, 
but not bad! One interesting aside was that one of the donated 
units was antibody-positive, requiring complete antibody 
identification prior to its release; this extra testing could 
have affected the turnaround time. Interestingly, the plasma 
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from this patient was then sent to the NRLBGS to be used 
as a source for screening donors. This shows the high level 
of collaboration within the members of the ARDP as well as 
within the international community.
Another challenge to the ARDP is providing blood that 
is negative for low-prevalence antigens, typically along with 
the blood also being negative for many common and possibly 
uncommon antigens. Ever-declining antisera resources for 
typing units, especially antisera for some of the low-prevalence 
antigens, has affected the ability of laboratories to perform 
these typings on units. Many frozen common antigen–
negative units sit in inventory; however, because they have 
not been tested for low-prevalence antigens and resources are 
unavailable, they are not usable for patients who have made an 
additional antibody to a low-prevalence antigen. Only through 
subsequent donations and molecular testing can these donors 
be tested and their units be made available for such requests. In 
the U.S., it is relatively easy to send a segment from an untested 
unit to the requesting ARDP facility for use in crossmatching 
or possibly in typing if the facility happens to have an antisera 
source. However, when providing units internationally, this 
practice is not expeditious or economically feasible. One 
patient in the UK, who was in sickle cell crisis, required a total 
of 12 units of group O, C–E–K–Fy(a–b–)s–Js(a–) RBCs (two 
different requests, 2 weeks apart). Twelve liquid units were 
found at five different ARDP facilities; however, not all of the 
units had been typed for Jsa. Processing this request ran into a 
weekend, and, at one facility, on-call staff was asked to go into 
the site and type the liquid units for Jsa to ensure shipment on 
Monday morning. It was a group effort, and all requested units 
were provided.
The introduction of molecular testing into the 
immunohematology arena in 2008 not only allowed for the 
identification of more common and uncommon antigens on a 
single donor sample, including low-prevalence antigens such 
as Jsa, Kpa, and Lua, but also provided a means to further 
characterize RH alleles of patients and donors, which greatly 
enhanced the ability to identify hrB– donors and provide 
genotype-matched units to patients with anti-hrB. As we have 
come to learn, there are many RHCE variants that cause the 
hrB– phenotype; antisera for hrB have never been characterized 
and are unreliable sources for screening donors. Educating 
the reference laboratory staff as well as physicians to the 
importance of molecular testing is ongoing. But over the last 
8 years, this initiative has increased the number of patients 
tested and the number of donors identified and has made it 
possible to provide tiered genotype-matched units for patients 
for whom few other options are available.3
There is a great difference in managing a request for a 
patient with anti-hrB in 2015 compared with 2008. In 2008, the 
ARDP had access to only a small database of 80 characterized 
donors who had been genotyped in response to patient needs 
rather than through mass screening.  With the variability of 
the RHD and RHCE genotypes, these 80 donors represented 
many diverse heterozygous combinations that frequently did 
not match the genotypes of the needy patients, which tended 
to be more homozygous. More characterized donors were 
needed. In addition, without the genotype of the patient, it was 
not possible to provide appropriate units.  Although the donor 
database began growing with the use of the mass-screening 
platforms in 2008 and 2009, patient testing lagged behind. 
My initial response to a request for a patient with anti-hrB or 
anti-hrS was, “Has the patient been genotyped?” At that time, 
most replies were negative, to which the importance of having 
the patient’s RHD and RHCE characterized was stressed to 
enable the ARDP to provide the best match for this patient. 
Efforts to educate the physicians and lab staff were productive, 
and the list of molecularly tested patients grew with the list 
of molecularly tested donors. The ARDP, with the help of the 
molecular testing, was moving in the right direction, in being 
able to provide genotype-matched units; it just wasn’t quite 
there yet. In this transition period, some requests for patients 
were answered with a report of the patient’s molecular results, 
but no identified donors. However, in the past few years, a 
request for a patient with anti-hrB was answered with a report 
of the patient’s molecular results, a search for tiered genotype-
matched donors, and very likely a liquid unit from a donor 
who “just happened to come in and donate.” These were 
the miracles that became more frequent with the advent of 
testing using molecular methods. Many hrB– patients are well 
served by this testing. However, hrS– patients are not quite as 
fortunate, since far fewer hrS– donors have been identified. 
Therefore, it is crucial that blood centers continue to invest in 
building the cohort of donors with full RH characterization for 
these patients.
One of the classic stories of the impact of molecular 
testing on providing units is that of a 4-year-old patient 
who, in 2005, was in need of a splenectomy. He was group 
O, D+ with anti-Jka and anti-hrB, which had not been 
characterized. Because he was E–, the physician requested 
that the units be E– as well. At that time, only four donors 
in the U.S. had been “identified” as being hrB– by serology: 
donors in California, Illinois, Florida, and Wisconsin. The 
four donors were contacted, and all attempted to donate; one 
was deferred. Samples from the patient and the four donors 
were sent to a molecular laboratory where the patient’s RHD 
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alleles were characterized as RHD*01/RHD-DIIIa-CE(4-
7)-D, and his RHCE alleles were found to be RHCE*ce733G/
RHCE*ce48C,733G,1006T.  The RHD allele DIIIa-CE(4-7)-D 
and the RHCE allele RHCE*ce48C,733G,1006T are often 
co-inherited, and the haplotype is often referred to as ŕ S. 
Although none of the donors were an exact match, three of 
the four donor samples were either RHD*01 or RHD-DIIIa-
CE(4-7)-D and homozygous for RHCE*ce48C,733G,1006T; 
therefore, RHD*01 RHCE*ce48C,733G,1006T homozygotes 
or r'S homozygotes, both of which were Tier 2 matches for the 
genotype of this patient. The liquid units were shipped, and 
the surgery took place. In 2010, the ARDP received another 
request for this patient. At that time, there were 74 hrB– Tier 1 
or 2 genotype-matched donors, making the search for units for 
this patient much easier.
Holidays and vacations were no exception to requests for 
rare blood, adding the challenge of short-staffed laboratories 
and modified flight schedules. In November 2013, while baking 
pumpkin pies on the day before Thanksgiving, I received a 
phone call from the on-call physician for a Chicago hospital, 
where a patient was in need of I– RBC units; the physician 
was calling from a beach in Florida where he was visiting 
family. Requests had been sent through the ARDP with no 
responses received from ARDP member facilities, the patient 
was worsening, and, of course, it was a holiday. Knowing that 
lab staffing was limited because of the holiday, and always 
with ARDP information at my side, I phoned the handful of 
sites with registered I– donors and found 3 units, which were 
then shipped. For another case, during Christmas week of 
2010, I was at home on the phone with the manager of the ARC 
National Molecular Laboratory (also at home), searching for 
units for a patient with end-stage renal disease who was group 
O, D+ with anti-C, anti-E, and anti-hrB. The patient’s RHD and 
RHCE alleles had been characterized, and her haplotype was 
determined to be DIIIa-ceS/ŕ S. At that time, there were about 
20 donors who would have been a Tier 1 or 2 genotype match 
for her; however, only 1 unit was available; it was shipped on 
December 27, 2010. Despite transfusion, the patient expired 
on January 1, 2011.
Shipping rare blood is not without its logistical challenges: 
shipments of rare blood have been delayed because of a 
tropical storm in the Gulf of Mexico preventing a flight from 
Miami to Trinidad; or because of a dog on board a flight, which 
prevented dry ice from being on the same plane; or because 
the scheduled flight switched to a smaller plane that had 
restrictions on the amount of dry ice that could be transported. 
Dealing with time zones across the U.S. and across the 
Atlantic or Pacific; pilots not allowing dry ice on passenger 
flights; shipments that “missed” the scheduled truck delivery; 
timing the shipment to make the last ferry ride from Seattle to 
Victoria, British Columbia; and the absence of customs officials 
onsite to receive and process the imported shipment added to 
delays and alternate plans as well. It was a logistical nightmare 
at times, but through numerous communication channels, the 
blood did arrive.
Much was learned through trial and error on how best 
to expedite shipments. Having made shipping arrangements 
for an international shipment only to find that the units 
were held up in processing changed how I managed these 
shipments; all units were physically observed before finalizing 
the arrangements to ensure that the units were typed, tagged, 
and physically ready to ship. A call to the courier for flight 
information typically began with the courier asking, “When 
can you have the blood shipment ready?” However, the best 
planning focused on the question, “When does the flight leave?” 
Once the flight departure time was established, we would 
work backwards from the flight time to allow driving time to 
the airport, the 2-hour required time for the shipment to be at 
the airport prior to flight time, and the time to pack the units. 
Although the blood was shipped in boxes that were validated 
for 48-hour transit time, either with wet ice for liquid units or 
dry ice for frozen units, the goal was always to minimize the 
time that the blood was in transit. 
Although many challenges exist, miracles do happen, 
and rare blood is shipped through the collaboration of many 
individuals and facilities. My sincere thanks go to all who 
answer the phone; respond to the e-mail; take the time to 
contact donors; collect, process, and test units; pack and ship 
the boxes; and provide rare blood in any way to the patients in 
need. You are a special group who make the ARDP the success 
that it is.
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